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COMPOSITIONS AND METHODS FOR 
DETECTING AND TREATING 
ATHEROSCLEROSIS 
This application claims the bene?t of priority to Provi 
sional Application 60/382,563, ?led May 24, 2002, Which is 
incorporated by reference in its entirety. 
FIELD OF THE INVENTION 
The invention relates to compositions and methods for the 
detection and treatment of atherosclerosis. In particular, the 
invention relates to compositions containing an inhibitor or 
antibody that binds speci?cally to Group V secretory phos 
pholipase (sPLA2). 
BACKGROUND OF THE INVENTION 
A critical event in early atherogenesis is the retention of 
loW density lipoprotein (LDL) particles in the subendothe 
lium through their binding intimal proteoglycans. These 
retained lipoprotein particles are exposed to several modify 
ing enZymes in the arterial Wall, including lipases, oxidiZing 
enZymes, and proteases. A multitude of biological responses 
to such modi?ed LDL, including the recruitment and lipid 
loading of macrophages, leads to the initiation and progres 
sion of atherosclerosis. The extracellular matrix (ECM) 
appears to play an active role in this process by not only 
mediating the retention of LDL particles, but by also modu 
lating the activity of various enZymes toWards LDL. Thus, in 
regions Where LDL is being accumulated, the co-localiZation 
of LDL, ECM and LDL modifying enzymes leads to a self 
perpetuating cascade of events that culminates in atheroscle 
ros1s. 
Within the arterial intima there are several proteolytic and 
lipolytic enZymes and oxidiZing agents that are capable of 
modifying LDL. The activity of these factors is likely respon 
sible for the prominent characteristics of LDL particles iso 
lated from atherosclerotic lesions, namely oxidation, enrich 
ment With sphingomyelin, and self-aggregation. 
Accumulating evidence points to LDL aggregation and 
fusion as elements of atherogenic lipid accumulation in the 
artery Wall. Aggregated lipoproteins that appear to be derived 
from LDL are prominent in early atherosclerotic lesions. 
Aggregated LDL is taken up by macrophages in vitro at an 
enhanced rate compared to non-aggregated LDL, leading to 
macrophage cholesterol accumulation and foam cell forma 
tion. Since native LDL particles do not form aggregates, LDL 
modi?cation appears to be a prerequisite for aggregation and 
fusion. It is notable that the aggregation/fusion of LDL par 
ticles proceeds faster in vitro When they are bound to pro 
teoglycans, and in turn, proteoglycan binding of modi?ed 
LDL is enhanced as a result of particle aggregation. Studies in 
vitro have demonstrated that treatment of LDL With sPLA2 
and secretory sphingomyelinase (s-SMase), induces LDL 
aggregation and/ or fusion and enhanced retention in the sub 
endothelium (Oomi, K et al., J Lipid Res, 2000. 41 (1 1):1703 
14). 
The phospholipases A2 (PLA2) family comprises a group 
of enZymes sharing the common feature of hydrolyZing the 
fatty acid esteri?ed at the sn-2 position of glycerophospho 
lipids. (Six, DA. and B. A. Dennis, Biochem. Biophys.Act., 
2000. 1488: 1-19). They are generally categoriZed into cyto 
solic or secretory forms. The secreted forms of the enZyme are 
of loW molecular Weight (14 kDA), highly enriched in disul 
?de bonds, and require 1-10 mM calcium for activity. The 
major secreted form present in synovial ?uid, termed Group 
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IIA (classically referred to as non-pancreatic secretory PLA2) 
has been proposed as a mediator of in?ammatory responses. 
During acute or chronic in?ammation, the concentration of 
Group IIA sPLA2 can increase by over 100-fold in in?amma 
tory ?uids and plasma. The expression of group IIA sPLA2 is 
Widely distributed in human tissues. In the arterial Wall, group 
IIA sPLA2 is expressed by vascular smooth muscle cells and 
is associated With heparin sulfate proteoglycans of the ECM 
Recently, a distinct sPLA2 in macrophages and mast cells 
has been described. Although it Was previously assumed that 
the sPLA2 in macrophages and mast cells is Group IIA, it is 
noW recogniZed that Group V sPLA2 is expressed by these 
cells. Like the Group IIA enZyme, Group V sPLA2 mRNA is 
greatly induced by proin?ammatory stimuli. Group V sPLA2 
exhibits high af?nity binding to proteoglycans that is medi 
ated by a cluster of cationic residues near the C-terminal end 
of the enZyme. The studies of Balboa et al. demonstrate that 
an antisera raised against the synovial sPLA2 (Group IIA) 
cross-reacts With Group V sPLA2 in P388Dl macrophages. 
This observation underscores the importance of developing 
molecular probes and antibodies to distinguish the individual 
enzymes. 
Immunohistochemistry studies have established that 
sPLA2 is present in normal arterial tissue and increased in 
atherosclerotic lesions. HoWever, there are some inconsisten 
cies betWeen these reports. In some reports, sPLA2 is pre 
dominantly associated With smooth muscle cells, Whereas in 
other reports, a signi?cant amount is detected in macroph 
ages. A possible explanation for the contradictory results may 
be the variable degree to Which available antibodies recogniZe 
Group IIA sPLA2 and the related form, Group V sPLA2. 
Group V sPLA2 shoWs a close structural relationship to 
Group IIA sPLA2. Nevertheless, these enZymes have distinct 
structural features that may exert important functional differ 
ences. Group V sPLA2 contains amino acid variations in the 
regions that have been shoWn to be important for the interfa 
cial binding of other sPLAZs. Binding studies using phos 
phatidylcholine (PC)-coated hydrophobic beads shoWed that 
human Group V sPLA2 binds PC membranes more than 
50-times more tightly than human Group IIA sPLA2. Indeed, 
it has been suggested that PC analogues may serve as selec 
tive inhibitors for Group V sPLA2, given the loW binding 
a?inity of other sPLA2s for PC substrates. In contrast to 
Group IIA sPLA2, Which has been shoWn to be very ineffec 
tive in hydrolyZing PC compared to other phospholipids, 
kinetic studies shoW that Group V sPLA2 effectively hydro 
lyZes PC-containing substrates. 
Thus, there is a need for probes and methods to distinguish 
the Group IIA and Group V sPLA2. There is also a need for 
methods and compositions to block LDL modi?cations that 
lead to LDL aggregation and/or fusion and increased mac 
rophage LDL uptake. 
SUMMARY OF THE INVENTION 
In one aspect of the invention there is provided an antibody 
raised against mouse Group V sPLA2 that speci?cally binds 
to lesional macrophages. 
In another aspect of the invention there is provided a 
method of assessing the risk of cardiovascular pathology in a 
patient comprising administering to the patient a monoclonal 
antibody speci?c for the human Group V sPLA2 enZyme, said 
antibody having a detectable label attached thereto; quanti 
fying the amount of Group V sPLA2 in plasma of a human 
patient and correlating the amount of Group V sPLA2 With the 
presence of unstable atherosclerotic plaques in the cardiovas 
cular system of the patient. 
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In yet another aspect of the invention there is provided a 
method for blocking the formation of aggregates of LDL in a 
patient, said method comprising administering to a patient an 
effective amount of an inhibitor of Group V sPLA2. 
In another aspect of the invention there is provided a 
method for preventing atherosclerotic lesion development, 
said method comprising administering to a patient an effec 
tive amount of an inhibitor of Group V sPLA2. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1A and FIG. 1B are schematic draWings of a proposed 
model for the role of Group V sPLA2 in promoting macroph 
age foam cell formation. 
FIGS. 2A (human) and 2B (mouse) shoW atherosclerotic 
lesions stained for either a macrophage-speci?c antigen 
(CD68, FA11) or Group V sPLA2. 40>< magni?cation. 
FIG. 3 is a bar graph shoWing sPLA2 activity produced by 
control and AdmGV-treated RAW and J 774 cells. 
FIG. 4A is a bar graph shoWing the free fatty acid (FFA) 
content of media after 24 hours incubation of COS-7 cells 
(AdmGV-treated and untreated) With 0.2 mg/ml LDL. FIG. 
4B is an autoradiograph shoWing siZe distribution of LDL 
particles after incubation. 
FIG. 5 is a graph shoWing LDL hydrolysis by puri?ed 
Group V sPLA2. 
FIGS. 6A and 6B are bar graphs shoWing the siZe distribu 
tion of unmodi?ed and Group V-modi?ed LDLs as assessed 
by electron microscopy. 
FIG. 7 shoWs the separation of LDLs before and after 
treatment With Group V sPLA2 by siZe exclusion chromatog 
raphy. 
FIG. 8 is a graph shoWing that the degree of particle aggre 
gation corresponds to the extent of particle hydrolysis. 
FIG. 9 is a series of photographs of peritoneal macrophages 
from C57BL/ 6 mice that Were incubated With non-modi?ed 
(mock) LDL, vortexed LDL, or Group V sPLA2-modi?ed 
LDL (~30% hydrolyZed) for 48 hours. Cells Were stained 
With Oil Red 0 and analyZed by light microscopy at 40x 
magni?cation. 
FIG. 10 is a Coomassie blue stained SDS 15% polyacry 
lamide gel on Which mouse Group V sPLA2 expressed in 
prokaryotic cells Was separated. The predicted molecular 
Weight of the Group V sPLA2 fusion protein expressed in the 
bacterial cells is ~17 kDa. 
FIG. 11 is an immunoblot of control COS-7 cells and cells 
after infection With AdmGV, Which expresses Group V 
sPLA2. Cells Were infected With an MOI of 40 pfu per cell. 
Aliquots corresponding to 10 micrograms of protein Were 
separated on 15% SDS PAGE, immunoblotted With rabbit 
anti-mouse Group V sPLA2, and visulaiZed by chemilumi 
nescence. 
DETAILED DESCRIPTION OF THE INVENTION 
Several lines of evidence suggest that sPLA2 modi?cation 
of LDL results in structural alterations of the particle that lead 
to atherogenic lipid accumulation in the subendothelium. 
Studies in vitro indicate that lipolysis of LDL With sPLA2 
results in partial liproprotein aggregation and increased a?in 
ity for proteoglycans. These effects are likely brought about 
by conformational changes in the apoB-100 moiety of LDL. 
In addition, sPLA2 modi?cation increases the susceptibility 
of LDL to hydrolysis by secretory sphingomyelinase 
(s-SMase). This leads to the accumulation of ceramide Within 
the particles, Which can also promote particle aggregation and 
fusion. Aggregated/ fused LDL, Which is prominent in athero 
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sclerotic lesions, is one of the most potent inducers of mac 
rophage foam cell formation in vitro. These modi?ed LDL 
particles are engulfed by macrophages in a process that 
involves the actin cytoskeleton. Thus, although it has not been 
directly shoWn, sPLA2 activity on LDL may promote athero 
genesis by generating potent inducers of macrophage foam 
cells in the arterial subendothelium. Which sPLA2 enZyme(s) 
produce these effects on LDL in vivo has not been conclu 
sively established. 
Group IIA sPLA2 has been shoWn to be present in athero 
sclerotic lesions associated With the ECM. Smooth muscle 
cells appear to be the main source of Group IIA sPLA2 in the 
arterial Wall. Although human recombinant Group IIA sPLA2 
is capable of hydrolyZing LDL in vitro, the activity of this 
enZyme toWards LDL is loW When compared to the hydrolysis 
mediated by bee venom sPLA2. It is notable that C57BL/6 
mice, a strain susceptible to diet-induced atherosclerosis, lack 
functional Group IIA sPLA2 as a result of a natural disruption 
of the gene. 
We noW shoW the presence of an additional sPLA2 in ath 
erosclerotic lesions, Group V sPLA2, Which is shoWn herein 
to be associated speci?cally With macrophages. These results 
suggest that the presence of Group V sPLA2 and LDL in the 
proximity of macrophages leads to the localiZed production 
of modi?ed LDL particles that have enhanced capacity for 
macrophage uptake, Which consequently leads to foam cell 
formation and enhanced atherosclerosis. 
The data provided herein suggest that LDL retained in the 
subendothelium is susceptible to hydrolysis by macrophage 
secreted Group V sPLA2 leading to the formation of small, 
dense LDL particles. These sPLA2-modi?ed LDL particles 
are susceptible to self-aggregation and fusion. In the arterial 
Wall, sphingomyelinase and/or ECM promotes Group V 
sPLA2-mediated effects on LDL aggregation and fusion. It is 
believed that modi?ed LDL particles are taken up by mac 
rophages to a greater extent than native LDL and that the 
mechanism of uptake of aggregated/fused particles is distinct 
from receptor-mediated endocytosis of native LDL. Thus, 
Group V sPLA2 provides an important neW target for the 
treatment of atherosclerotic disease. Use of inhibitors of 
Group V sPLA2 to prevent the formation of aggregates of 
LDL is encompassed by the present invention. Such inhibi 
tors include, but are not limited to anti-Group V sPLA2 anti 
bodies, other compounds, such as phosphatidylcholine ana 
logs, that bind to Group V sPLA2 and antisense 
oligonucleotides that speci?cally bind to and prevent trans 
lation of Group V sPLA2 mRNA. Such compounds can be 
identi?ed by testing compounds for their ability to bind to 
Group V sPLA2 and inhibit LDL modi?cation in vitro. 
The speci?c dose of an inhibitor compound administered 
according to this invention to obtain therapeutic or prophy 
lactic effects Will, of course, be determined by the particular 
circumstances surrounding the case, including, for example, 
the compound administered, the route of administration and 
the condition being treated. Typical daily doses Will contain a 
non-toxic dosage level of from about 0.01 mg/kg to about 50 
mg/kg of body Weight of an active compound of this inven 
tion. 
Preferably inhibitor compounds or pharmaceutical formu 
lations containing these compounds are in unit dosage form 
for administration to a mammal. The unit dosage form can be 
a capsule or tablet itself, or the appropriate number of any of 
these. The quantity of active ingredient in a unit dose of 
composition may be varied or adjusted from about 0.1 to 
about 1000 milligrams or more according to the particular 
treatment involved. It may be appreciated that it may be 
necessary to make routine variations to the dosage depending 
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on the age and condition of the patient. The dosage Will also 
depend on the route of administration. 
The compound can be administered by a variety of routes 
including oral, aerosol, rectal, transdermal, subcutaneous, 
intravenous, intramuscular, and intranasal. 
Group V sPLA2 is shoWn herein to associate speci?cally 
With macrophages in human and mouse atherosclerotic 
lesions. The proposed role of Group V sPLA2 in promoting 
the accumulation of atherogenic lipid in the developing ath 
erosclerotic plaque is shoWn in FIG. 1. In the proposed model 
native LDL in the circulation migrates into the intima and 
associates With proteoglycans. Group V sPLA2 secreted by 
macrophages also bind proteoglycans, Where it has the capac 
ity to hydrolyZe phospholipids on LDL. Group V sPLA2 
modi?ed LDL binds proteoglycans With higher a?inity and is 
subject to further modi?cations, leading to aggregation/fu 
sion of particles. Such LDL modi?cations promote uptake by 
macrophages, leading to foam cells. 
A monoclonal antibody speci?c for the human Group V 
enZyme is shoWn herein to clearly stain macrophages in 
human atherosclerotic lesions. A polyclonal antibody raised 
against mouse Group V sPLA2 also demonstrates speci?c 
staining of lesional macrophages in a mouse that lacks Group 
11A sPLA2. FIG. 2 shoWs immunostaining of Group V sPLA2 
in human (A) and mouse (B) atherosclerotic lesions. FA-l 1 is 
a monoclonal antibody Which is speci?c for macrosialin, the 
mouse homologue of the human macrophage-speci?c anti 
gen CD68. Serial sections treated With no primary antibody 
(A) or pre-immune antisera (B) shoWed no staining. Such 
antibodies canbe used to detect atherosclerotic plaques and to 
quantitate the amount of Group V sPLA2 in plasma. For 
example, an anti-Group V sPLA2 antibody may be added to a 
tissue or plasma sample obtained from a patient in order to 
detect the presence of Group V sPLA2. The amount of anti 
body detected can then be correlated to the amount of Group 
VsPLA2 in the plasma. The anti-Group V sPLA2 speci?c 
antibody can be tagged With a detectable label or a second 
antibody that binds to the anti-Group V sPLA2 antibody can 
be used to detect the bound anti-group V sPLA2 antibody. 
Development of Adenoviral Vector Expressing Mouse Group 
V sPLA2 
Use of viral vectors provides a rapid and ef?cient technique 
for over-expressing proteins in macrophages, a cell type that 
is di?icult to stably transfect using plasmid constructs. A 
replication-de?cient adenoviral vector encoding mouse 
Group V sPLA2, AdmGV, Was constructed using methods 
knoWn to those of skill in the art (see Maniatis, Molecular 
Cloning, A Laboratory Manual for methods; Genbank for 
mouse Group V sPLA2 nucleotide sequence) and used to 
investigate the effect of AdmGV treatment on secreted phos 
pholipase activity in mouse macrophage lines (FIG. 3). Cells 
Were treated With AdmGV at a multiplicity of infection 
(MOI) of 40 or 100 pfu per cell. After 48 hours of treatment, 
culture supernatants Were collected and assayed for phospho 
lipase activity using a coliormetric assay (WAKO). Mixed 
micells comprising 1-palmitoyl, 2-oleoyl phosphatidylglyc 
erol (POPG), deoxycholate and noniodet-40 Were used as 
substrate. Values Were expressed as the amount of FFA 
released in the assay per ml of culture media. At the higher 
dose of adenovirus, sPLA2 activity Was increased over base 
line values 4.4-fold and 42-fold in RAW and 1774 cells, 
respectively. 
LDL is HydrolyZed by Mouse Group V sPLA2 Expressed by 
Adenoviral Vector 
Whether Group V sPLA2 expressed by adenoviral vector 
hydrolyZes LDL Was investigated. COS-7 cells Were treated 
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With AdmGV or control virus, Adnull. TWenty-four hours 
after adenovirus treatments, cells Were incubated an addi 
tional 24 hours With media containing 0.2 mg/ml 125l-LDL 
(0.4 pM). The extent of LDL hydrolysis Was assessed by 
measuring the free fatty acid (FFA) content of media. As 
shoWn in FIG. 4A, a signi?cant amount of FFA Was liberated 
When LDL Was added to Group V sPLA2-expressing cells. 
The data indicate that approximately 85 molecules of FFA 
Were generated per particle of LDL added. Analysis by non 
denaturing gradient gel electrophoresis shoWed that LDLs 
incubated With Group V sPLA2-expressing cells migrated as 
smaller lipoprotein particles compared to control LDLs (FIG. 
4B). 
Group V sPLA2-Modi?ed LDL Undergoes Spontaneous 
Aggregation and Promotes Macrophage Foam Cell Forma 
tion 
Partially puri?ed Group V sPLA2 enZyme Was prepared 
from media collected from AdmGV-treated COS cells by 
sequential chromatograpy on Hi-Trap SP ion-exchange and 
Hi-Trap heparin columns. Hydrolytic activity of the eluted 
material Was assessed using POPG and LDL as substrates. 
LDL (0.5 mg/ml; 1 pM) Was incubated for 20 hours at 37° C. 
in buffer containing 6 mM HEPES, 6 mM CaCl2, 2.4 mM 
MgCl2, 84 mM NaCl and 2% (Wt/vol) BSA With and Without 
added enZyme. The amount of FFA acids generated Was mea 
sured using a colorimetric assay. One unit of GV sPLA2 Will 
generate 1 nmole of FFA per minute using POPG as substrate. 
At maximal hydrolysis, GroupV sPLA2 generated ~1 nmol 
FFA per pg LDL. Assuming 1.4 nmol phospholipid per pg 
LDL, this represents ~70% hydrolysis by Group V sPLA2. 
FIG. 5. 
Analysis of LDL particles by electron microsopy after 
negative staining shoWed that LDL particles hydrolyZed by 
Group V sPLA2 are signi?cantly smaller compared to control 
LDLs. This ?nding is signi?cant, since small dense LDL 
particles have increased a?inity for proteoglycans and are 
thereby retained in the vessel Wall subendothelium. Mean 
diameters (:SD) of unmodi?ed and modi?ed LDLs (~200 
particles per group) Were 27.7 (10.25) nm and 25.3 (10.29) 
nm, respectively (P<0.001). FIGS. 6A and 6B. 
To assess Whether hydrolysis leads to spontaneous particle 
aggregation and/or fusion, LDLs Were separated before and 
after treatment With Group V sPLA2 by siZe exclusion chro 
matography. Aggregated/ fused particles elute in the void vol 
ume of a Superose 6 gel ?ltration column. The analysis of 
unmodi?ed LDL and maximally modi?ed LDL shoWed that a 
large portion (>50%) of the modi?ed LDL Was in an aggre 
gated form. The presence of LDL aggregates Was con?rmed 
by electron microscopy. FIG. 7. 
Aliquots containing 75 pg unmodi?ed LDL or LDL treated 
With Group V sPLA2 (~70% phospholipids hydrolyZed) Were 
separated on a Superose 6 column, and the cholesterol content 
of 0.5 ml fractions Was determined. (inset of FIG. 7): Nega 
tive staining and electron microscopy of mGV sPLAZ-modi 
?ed LDL particles is shoWn in FIG. 7. 
Further analysis of sPLA2-modi?ed LDL revealed that the 
degree of particle aggregation is proportional to the percent of 
phospholipids hydrolyZed. An analysis of Group V sPLA2 
hydrolyZed LDL particles shoWs a positive correlation 
betWeen the extent of particle hydrolysis and the degree of 
particle aggregation. FIG. 8. 
Aggregated LDL, such as that produced by vortexing, has 
been shoWn to be the most potent inducer of macrophage 
foam cells. Kramer, R. M., et al., J Biol Chem, 1989. 264(10): 
p. 5768-75. Thus, it Was of interest to determine Whether 
Group V sPLA2-modi?ed LDL particles that are susceptible 
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to spontaneous aggregation promote foam cell formation in 
vitro. Peritoneal macrophages from C57BL/ 6 mice Were 
incubated With non-modi?ed (mock) LDL, aggregated LDL 
produced by vortexing, or Group V sPLAZ-modi?ed LDL 
(~30% hydrolyzed) for 48 hours. Cells Were stained With Oil 
Red 0 and analyZed by light microscopy at 40x magni?cation. 
FIG. 9. This analysis shoWed that Group V sPLAZ-modi?ed 
LDL promotes macrophage foam cell formation, providing 
compelling evidence that this enZyme plays an important role 
in the initiation and/ or progression of atherosclerosis. 
Modi?cation of LDL by Group V sPLA2 promotes lipid 
uptake by peritoneal macrophage cells. Mouse peritoneal 
macrophage cells Were plated (1 .8><106 cells/Well) in DMEM 
complete media on glass cover slips in a 6 Well dish. Non 
adherent cells Were removed by Washing With serum free 
DMEM after 4 hours at 370 C., and adherent cells Were 
stimulated With 1 mM MCSF for 16 hours. Cells Were then 
treated With 200 g/ml unmodi?ed LDL, vortexed LDL, or 
Group V sPLA2 modi?ed LDL. After 48 hours at 370 C., cells 
Were Washed With PBS, ?xed With 10% formalin for 10 min 
utes, and Washed With 60% isopropanol. The cells Were 
stained With oil Red 0 for 30 minutes and Washed again With 
60% isopropanol. The cells Were then visualiZed With light 
microscopy at 40x magni?cation. The results are shoWn in 
FIG. 9. 
Development of Rabbit Anti-Mouse Group V sPLA2 
To produce rabbit antisera speci?c for mouse Group V 
sPLA2, sequences encoding residues 9-1 13 Were inserted into 
the bacterial expression plasmid pET22b (Novagen, Madi 
son, Wis.). The expressed protein contained a C-terminal 
His'Tag, Which alloWed for one-step puri?cation by a?inity 
chromatography. As shoWn in FIG. 10, use of this prokaryotic 
expression system provided an e?icient method for produc 
ing antigen for immuniZing rabbits. The pET system is also 
used to express full-length mouse Group V sPLA2, Which 
may be puri?ed from bacterial inclusion bodies by gel ?ltra 
tion (Dr. E. A. Dennis, personal communication). The immu 
noreactivity of rabbit anti-mouse Group V antisera is demon 
strated in FIG. 11, Which shoWs immunoblot analysis of total 
cell lysates from control COS-7 cells and cells infected With 
adenoviral vector expressing mouse Group V sPLA2. Anti 
Group V antisera can be used in the same manner as anti 
Group V sPLA2 antibodies to detect and/ or quantitate Group 
V sPLA2 in tissue or serum. 
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lmmunocytochemical LocaliZation of Group V sPLA2 in 
Human and Mouse Atherosclerotic Lesions 
As described above, several reports have identi?ed sPLA2 
in human atherosclerotic lesions. HoWever, there are incon 
sistencies in the data as to Whether sPLA2 is associated With 
macrophages or smooth muscle cells (SMC) in lesions. This 
may be attributed to the cross-reactivity of various antibodies 
With Group 11A and Group V sPLAZs. Here We used a mono 
clonal antibody shoWn to be highly speci?c for human Group 
V sPLA2 (Cayman Chemicals, Ann Arbor Mich.) to immun 
ostain human atherosclerotic lesions. This antibody, Which 
does not cross-react With Group 11A sPLA2 displayed strong 
immunoreactivity (red staining) in lesional macrophages 
(compare the staining When sections Were immunostained 
With anti-CD68, a macrophage-speci?c antigen; FIG. 2A, but 
not in SMC. A neWly developed rabbit anti-mouse polyclonal 
antibody Was also generated by art knoWn methods and used 
to stain lesions in apoE_/_ mice. These mice are in the 
C57BL/ 6 background, and therefore lack Group 11A sPLA2 
due to a frame-shift mutation in exon 3. As shoWn in FIG. 2B, 
immunostaining With anti-mouse Group V sPLA2 co-local 
iZed With the macrophage-speci?c monoclonal antibody, 
FA-l 1. 
What is claimed is: 
1. A method of diagnosing the presence of atherosclerotic 
plaques in a patient comprising: 
(1) obtaining a subendothelial tissue sample from the 
patient; 
(2) contacting the tissue sample With a ?rst antibody or 
antibody fragment that speci?cally binds to human 
Group V sPLA2; and 
(3) detecting binding of the antibody or antibody fragment 
to the tissue sample. 
2. The method of claim 1 Wherein the ?rst antibody or 
antibody fragment has a detectable label attached thereto. 
3. The method of claim 1 Wherein the ?rst antibody or 
antibody fragment is detected by contacting the tissue sample 
With a second antibody that binds to the ?rst antibody or 
antibody fragment, Wherein said second antibody has a 
detectable label attached thereto. 
4. The method of claim 1 Wherein the ?rst antibody or 
antibody fragment is detected by contacting the sample With 
a chemical entity that binds to the ?rst antibody or antibody 
fragment, Wherein the chemical entity has a detectable label 
attached thereto. 
